Ke-Xing Xi1,2, Ying-Sheng Wen1,2, Chong-Mei Zhu2,3, Xiang-Yang Yu1,2, Rong-Qing Qin4, Xue-Wen Zhang2,5, Yong-Bin Lin1,2, Tie-Hua Rong1,2, Wei-Dong Wang1,2, Yong-Qiang Chen1,2, Lan-Jun Zhang1,2. 1. Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 2. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China. 3. Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. 4. Department of Medical Oncology, The Affiliated Hospital Of Hangzhou Normal University, Hangzhou 310015, China. 5. Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
Abstract
BACKGROUND: In recent years, the tumor-stroma ratio (TSR) has been considered to a new and independent predictive variable for the prognosis of some kinds of neoplasms. The objective of this study was to assess the prognostic significance of the TSR in non-small cell lung cancer (NSCLC). METHODS: A cohort of 261 NSCLC patients who underwent radical surgery of lung cancer were included in the present study. Two independent observers visually estimated the TSR on hematoxylin-eosin (H&E) stained tissue pathological slices. According to the proportion of stroma ≥50% or <50%, We separate the patients into two groups: those with stroma-poor and those with stroma-rich tumors. RESULTS: Both univariate and multivariate analyses disclosed that the TSR was associated with overall survival (OS) [hazard ratio (HR), 1.741; 95% confidence intervals (CI), 1.040-2.913 and HR, 1.904; 95% CI, 1.132-3.202, respectively]. The HR values for disease-free survival (DFS) were 1.795 (95% CI, 1.073-3.005) and 2.034 (95% CI, 1.210-3.420). The OS and DFS of patients with stroma-poor tumors were better than those with stroma-rich tumors. CONCLUSIONS: These results demonstrated that the TSR is a new prognostic factor for NSCLC. Stroma-poor tumors were associated with longer disease-free period and better prognosis than were stroma-rich tumors in NSCLC patients. The TSR may contribute to the development of individualized treatment for NSCLC in the future.
BACKGROUND: In recent years, the tumor-stroma ratio (TSR) has been considered to a new and independent predictive variable for the prognosis of some kinds of neoplasms. The objective of this study was to assess the prognostic significance of the TSR in non-small cell lung cancer (NSCLC). METHODS: A cohort of 261 NSCLC patients who underwent radical surgery of lung cancer were included in the present study. Two independent observers visually estimated the TSR on hematoxylin-eosin (H&E) stained tissue pathological slices. According to the proportion of stroma ≥50% or <50%, We separate the patients into two groups: those with stroma-poor and those with stroma-rich tumors. RESULTS: Both univariate and multivariate analyses disclosed that the TSR was associated with overall survival (OS) [hazard ratio (HR), 1.741; 95% confidence intervals (CI), 1.040-2.913 and HR, 1.904; 95% CI, 1.132-3.202, respectively]. The HR values for disease-free survival (DFS) were 1.795 (95% CI, 1.073-3.005) and 2.034 (95% CI, 1.210-3.420). The OS and DFS of patients with stroma-poor tumors were better than those with stroma-rich tumors. CONCLUSIONS: These results demonstrated that the TSR is a new prognostic factor for NSCLC. Stroma-poor tumors were associated with longer disease-free period and better prognosis than were stroma-rich tumors in NSCLC patients. The TSR may contribute to the development of individualized treatment for NSCLC in the future.
Entities:
Keywords:
Non-small cell lung cancer (NSCLC); prognosis; tumor microenvironment; tumor-stroma ratio (TSR)
Authors: Wilma E Mesker; Jan M C Junggeburt; Karoly Szuhai; Pieter de Heer; Hans Morreau; Hans J Tanke; Rob A E M Tollenaar Journal: Cell Oncol Date: 2007 Impact factor: 6.730
Authors: Yue Du; Roy Zhang; Abolfazl Zargari; Theresa C Thai; Camille C Gunderson; Katherine M Moxley; Hong Liu; Bin Zheng; Yuchen Qiu Journal: Ann Biomed Eng Date: 2018-07-26 Impact factor: 3.934
Authors: Peggi M Angel; Evelyn Bruner; Jennifer Bethard; Cassandra L Clift; Lauren Ball; Richard R Drake; Carol Feghali-Bostwick Journal: J Mass Spectrom Date: 2020-02-21 Impact factor: 1.982
Authors: Sophie C Hagenaars; Kiki M H Vangangelt; Gabi W Van Pelt; Zsófia Karancsi; Rob A E M Tollenaar; Andrew R Green; Emad A Rakha; Janina Kulka; Wilma E Mesker Journal: Breast Cancer Res Treat Date: 2022-04-16 Impact factor: 4.624
Authors: Kiki M H Vangangelt; Andrew R Green; Isabelle M F Heemskerk; Danielle Cohen; Gabi W van Pelt; Marcelo Sobral-Leite; Marjanka K Schmidt; Hein Putter; Emad A Rakha; Rob A E M Tollenaar; Wilma E Mesker Journal: Int J Cancer Date: 2020-01-22 Impact factor: 7.396